Please use analysis of PDL BioPharma fundamentals to determine if markets are correctly pricing the firm. We found thirty-seven available financial ratios for PDL BioPharma which can be compared to its competitors. To make sure the equity is not overpriced, please check all PDL BioPharma fundamentals including its Price to Book, Total Debt, Number of Employees, as well as the relationship between EBITDA and Cash Flow from Operations . Given that PDL BioPharma has Price to Earning of 3.38X, we recommend you check out PDL BioPharma recent market performance to make sure the company can sustain itself for few more years. Use PDL BioPharma to enhance returns of your portfolios. The stock experiences moderate upward volatility. Check odds of PDL BioPharma to be traded at $3.51 in 30 days.
PDL BioPharma Company Summary
PDL BioPharma competes with China Cord, Equillium, NantKwest, DelMar Pharmaceuticals, and Denali Therapeutics. PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 104 people.
PDL BioPharma Retained Earnings vs Revenue
PDL BioPharma is considered to be number one stock in retained earnings category among related companies. It is regarded second in revenue category among related companies totaling about 0.15 of Revenue per Retained Earnings. The ratio of Retained Earnings to Revenue for PDL BioPharma is roughly 6.65
PDL BioPharma Systematic Risk